Dasatinib functions by inhibiting multiple tyrosine kinases, including BCR-ABL, which is a fusion gene formed from parts of the BCR and ABL genes. This fusion gene is responsible for the uncontrolled division of cancer cells in CML and ALL. By blocking these kinases, Sprycel effectively slows down or stops the growth of cancer cells.